EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1751-1760

  Lal, Bachchu ^a   Goodwin, C Rory ^a   Sang, Yingying ^a   Foss, Catherine A ^a   Cornet, Kathrine ^a   Muzamil, Sameena ^a   Pomper, Martin G ^a   Kim, Jin ^b   Laterra, John ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Galaxy Biotech Inc   (United States)

^c KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8 INHIBITOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5G8; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DELETION MUTANT; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; GLIOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MICE; MICE, KNOCKOUT; MICE, NUDE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651174457     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0188     Document Type: Article

References (38)

1. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
2. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
3. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
4. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90.
5. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
6. Laterra J, Nam M, Rosen E, et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997;76:565-77.
7. Lamszus K, Schmidt NO, Jin L, et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer 1998;75:19-28.
8. Bardelli A, Longati P, Albero D, et al. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J 1996;15:6205-12.
9. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8.
10. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.
11. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
12. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
13. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93.
14. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-9.
15. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994;91:7727-31.
16. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-9.
17. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to γ-radiation. Clin Cancer Res 2005;11:4479-86.
18. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
19. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007;67:3970-5.
20. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Faseb J 2002;16:108-10.
21. Tzourio N, Joliot M, Mazoyer BM, Charlot V, Sutton D, Salamon G. Cortical region of interest definition on SPECT brain images using X-ray CT registration. Neuroradiology 1992;34:510-6.
22. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 2006;12:2264-71.
23. Reznik TE, Sang Y, Ma Y, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008;6:139-50.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
25. Kearns EA, Simonson LG, Schutt RW, Johnson MJ, Neil LC. Characterization of monoclonal antibodies to two Treponema denticola serotypes by the indirect fluorescent-antibody assay. Microbios 1991;65:147-53.
26. Learn CA, Hartzell TL, Wikstrand CJ, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004;10:3216-24.
27. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
28. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008;105:692-7.
29. Bonine-Summers AR, Aakre ME, Brown KA, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007;6:561-70.
30. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFR-vIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A 2007;104:12867-72.
31. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 1999;96:1415-20.
32. Varmus H. The new era in cancer research. Science 2006;312:1162-5.
33. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005;4:1369-72.
34. Shapiro GIHE, Malburg L, DeZube B, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administrated daily to patients with advanced malignancies. 2007.
35. http://www.exelixis.com/pipeline-xl184.shtml. [cited; Available from: http://www.exelixis.com/pipeline-xl184.shtml].
36. ArQule I. A summary of the clinical findings of selective c-MET inhibitor ARQ197, providing clinical "proof of concept" for the use of a selective c-MET inhibitor. 2008 [cited; Available from: http://phx.corporate-ir. net/phoenix.zhtml?c=82991&p=irol-presentations].
37. Garcia ARL, Cunningham CC, Nemunaitis J, et al. Phase Ist udy of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J Clin Oncol 2007;25:144s.
38. Gordon MSMD, Sweeney C, Erbeck N, et al. Interim results from a first-in-human study with AMG102, a full human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumors. J Clin Oncol 2007;25:150s.